Table of Content



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Usher Syndrome - Overview
Usher Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Usher Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Usher Syndrome - Companies Involved in Therapeutics Development
Amgen Inc
Clearside BioMedical Inc
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Odylia Therapeutics Inc
ProQR Therapeutics NV
Wave Life Sciences Ltd
Usher Syndrome - Drug Profiles
ASO-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BF-844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDIT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLRN1 for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CLRN1 for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate USH1C for Usher Syndrome 1C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate USH1G for Usher Type I Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate USH2A for Retinitis Pigmentosa and Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate USH2A for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate USH2A for Usher Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QR-411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-421a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Usher Syndrome - Dormant Projects
Usher Syndrome - Discontinued Products
Usher Syndrome - Product Development Milestones
Featured News & Press Releases
May 02, 2019: Eloxx Pharmaceuticals presents positive new data at the Association for Research in Vision and Ophthalmology “ARVO” 2019 Annual Meeting
Jul 05, 2017: ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Desigtion from FDA and EMA
May 01, 2017: ProQR to Present Data on QRX-411 at ARVO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures



Number of Products under Development for Usher Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables



Number of Products under Development for Usher Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Usher Syndrome - Pipeline by Amgen Inc, H1 2020
Usher Syndrome - Pipeline by Clearside BioMedical Inc, H1 2020
Usher Syndrome - Pipeline by Editas Medicine Inc, H1 2020
Usher Syndrome - Pipeline by Eloxx Pharmaceuticals Inc, H1 2020
Usher Syndrome - Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Usher Syndrome - Pipeline by Odylia Therapeutics Inc, H1 2020
Usher Syndrome - Pipeline by ProQR Therapeutics NV, H1 2020
Usher Syndrome - Pipeline by Wave Life Sciences Ltd, H1 2020
Usher Syndrome - Dormant Projects, H1 2020
Usher Syndrome - Discontinued Products, H1 2020